Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 8/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30413993 | 1.00 | KAT2B (0.64) | KAT2BPOLBPRSS1MAPTPKM | |
| SCHEMBL2228171 | 1.00 | KAT2B (0.64) | KAT2BPOLBPRSS1MAPTPKM | |
| SCHEMBL17923845 | 1.00 | KAT2B (0.64) | KAT2BPOLBPRSS1MAPTPKM | |
| Hydrochloric Acid SCHEMBL4699216 | 0.99 | KAT2B (0.65) | KAT2BPOLBPRSS1MAPTPKM | |
| SCHEMBL2228520 | 0.99 | KAT2B (0.66) | KAT2BPOLBPRSS1MAPTPKM | |
| SCHEMBL10622798 | 0.94 | KAT2B (0.72) | KAT2BPOLBPRSS1MAPTPKM | |
| SCHEMBL1344180 | 0.93 | KAT2B (0.60) | KAT2BPOLBPRSS1MAPTPKM | |
| Hydrochloric Acid SCHEMBL21273381 | 0.92 | KAT2B (0.61) | KAT2BPOLBPRSS1MAPTPKM | |
| SCHEMBL29375013 | 0.88 | KAT2B (0.58) | KAT2BPOLBPRSS1MAPTPKM | |
| SCHEMBL502704 | 0.88 | KAT2B (0.58) | KAT2BPOLBPRSS1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| CN-110545850-A | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB | 2019-12-06 | — | — | CN | disclosed |
| US-20180360974-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2018-12-20 | — | — | US | disclosed |
| WO-2018163131-A1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2018-09-13 | — | — | WO | disclosed |
| EP-2056758-A2 | EPOXY-CONTAINING POLY(ESTER AMIDES) AND METHODS OF USE | Medivas, LLC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080050419-A1 | Epoxy-containing poly(ester amides) and method of use | MEDIVAS, LLC (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2008021548-A2 | EPOXY-CONTAINING POLY(ESTER AMIDES) AND METHODS OF USE | MEDIVAS, LLC (US) | 2008-02-21 | — | — | WO | disclosed |
| US-5258507-A | FOR IN SITU DETECTION OF NUCLEIC ACID SEQUENCES | AMOCO CORPORATION (US) | 1993-11-02 | — | — | US | disclosed |
| EP-0485155-A1 | Novel labeling reagents useful for the chemical attachment of nitrophenyl derivative ligands to DNA probes | AMOCO CORPORATION (US) | 1992-05-13 | — | — | EP | disclosed |
| US-4100028-A | Method for purification of proteolytic enzymes | STEPANOV VALENTIN MIKHAILOVICH | 1978-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360974-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | KAT2B 1285/4885POLB 1863/4885PRSS1 1498/4885 |
| US-20080050419-A1 | Epoxy-containing poly(ester amides) and method of use | EPHX2, JMJD6, CAD | KAT2B 1184/4885POLB 4474/4885PRSS1 3322/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | KAT2B 1285/4885POLB 1863/4885PRSS1 1498/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | KAT2B 1285/4885POLB 1863/4885PRSS1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.